Pediatrix Medical Group, Inc. (NYSE:MD) Receives $10.30 Consensus Target Price from Brokerages

Pediatrix Medical Group, Inc. (NYSE:MD - Get Free Report) has been assigned an average rating of "Hold" from the four ratings firms that are currently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold rating. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $10.30.

Several research analysts have commented on MD shares. Jefferies Financial Group lowered their price objective on shares of Pediatrix Medical Group from $10.00 to $9.00 and set a "hold" rating for the company in a research report on Wednesday, March 6th. Mizuho lowered their price target on shares of Pediatrix Medical Group from $10.00 to $9.00 and set a "neutral" rating for the company in a report on Wednesday, February 21st. TheStreet downgraded shares of Pediatrix Medical Group from a "c" rating to a "d" rating in a report on Friday, February 23rd. Finally, Truist Financial lowered their price target on shares of Pediatrix Medical Group from $10.50 to $10.00 and set a "hold" rating for the company in a report on Wednesday, February 21st.

Pediatrix Medical Group Stock Performance

NYSE MD traded down $0.35 during trading on Thursday, reaching $8.89. 424,741 shares of the company's stock were exchanged, compared to its average volume of 693,169. The business has a 50 day moving average price of $9.21 and a 200-day moving average price of $9.64. The stock has a market capitalization of $747.03 million, a P/E ratio of -12.34, a PEG ratio of 2.54 and a beta of 1.58. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.24 and a quick ratio of 1.24. Pediatrix Medical Group has a fifty-two week low of $7.70 and a fifty-two week high of $15.06.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 20th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.30 by $0.02. Pediatrix Medical Group had a positive return on equity of 10.35% and a negative net margin of 3.03%. The company had revenue of $496.44 million during the quarter, compared to analysts' expectations of $524.30 million. During the same quarter in the previous year, the company posted $0.46 earnings per share. The business's revenue was down 3.4% on a year-over-year basis. Sell-side analysts forecast that Pediatrix Medical Group will post 1.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pediatrix Medical Group

Several large investors have recently added to or reduced their stakes in the business. Invenomic Capital Management LP lifted its position in Pediatrix Medical Group by 93.3% in the 4th quarter. Invenomic Capital Management LP now owns 1,377,951 shares of the company's stock valued at $12,815,000 after acquiring an additional 664,955 shares in the last quarter. Aristides Capital LLC purchased a new stake in Pediatrix Medical Group in the 4th quarter valued at about $246,000. Campbell & CO Investment Adviser LLC increased its stake in Pediatrix Medical Group by 334.9% in the 4th quarter. Campbell & CO Investment Adviser LLC now owns 96,163 shares of the company's stock valued at $894,000 after buying an additional 74,049 shares during the last quarter. Clark Estates Inc. NY purchased a new stake in Pediatrix Medical Group in the 4th quarter valued at about $3,302,000. Finally, Connable Office Inc. purchased a new stake in Pediatrix Medical Group in the 4th quarter valued at about $217,000. Institutional investors own 97.71% of the company's stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.